Patir P, Vural F. Treatment of mycosis fungoides, in the era of stem cell transplantation. World J Dermatol 2016; 5(1): 52-56 [DOI: 10.5314/wjd.v5.i1.52]
Corresponding Author of This Article
Filiz Vural, MD, Department of Hematology, Ege University Hospital, Kazimdirik district, Bornova, 35100 Izmir, Turkey. fivural@yahoo.com
Research Domain of This Article
Hematology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Dermatol. Feb 2, 2016; 5(1): 52-56 Published online Feb 2, 2016. doi: 10.5314/wjd.v5.i1.52
Treatment of mycosis fungoides, in the era of stem cell transplantation
Pusem Patir, Filiz Vural
Pusem Patir, Filiz Vural, Department of Hematology, Ege University Hospital, Bornova, 35100 Izmir, Turkey
Author contributions: All authors equally contributed to this paper with conception and literature review, and critical revision and editing, and final approval of the final version.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Filiz Vural, MD, Department of Hematology, Ege University Hospital, Kazimdirik district, Bornova, 35100 Izmir, Turkey. fivural@yahoo.com
Telephone: +90-532-5468368 Fax: +90-232-3903530
Received: September 1, 2015 Peer-review started: September 2, 2015 First decision: September 29, 2015 Revised: October 30, 2015 Accepted: December 9, 2015 Article in press: December 11, 2015 Published online: February 2, 2016 Processing time: 150 Days and 13.2 Hours
Abstract
Mycosis fungoides and Sèzary syndrome are the most common subtypes of cutaneous T-cell lymphomas. Even though, in early-stage disease, Mycosis fungoides commonly has a more indolent course, disease will progress in about 20% of such patients. About 30% of patients have been reported to develop advanced-stage disease and, at present, there is no cure for the disease. A number of systemic approaches have been used for advanced-stage mycosis fungoides (IIB-IV) and transformed disease. Aggressive approaches seem to be warranted in such patients. The scope of this review is the stem cell transplantation in mycosis fungoides and its leukemic variant, Sèzary syndrome.
Core tip: Some cutaneous T-cell lymphoma patients progress to advanced-stage disease or leukaemic stages. To date, there is no cure for those cases. In the last few years, several publications reported durable responses in some patients following allogeneic hematopoietic stem cell transplantation. Our aim is to define outcomes after hematopoietic stem cell transplantation for mycosis fungoides and Sèzary syndrome.